Atwood & Palmer Inc. Lowers Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Atwood & Palmer Inc. decreased its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 1.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 63,696 shares of the biotechnology company's stock after selling 879 shares during the period. Atwood & Palmer Inc. owned about 0.14% of United Therapeutics worth $19,636,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. bought a new stake in United Therapeutics during the 4th quarter valued at $25,000. Dunhill Financial LLC grew its holdings in United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 50 shares during the last quarter. State of Wyoming acquired a new position in United Therapeutics during the 4th quarter valued at about $62,000. Curat Global LLC purchased a new position in shares of United Therapeutics in the 1st quarter valued at approximately $63,000. Finally, Millstone Evans Group LLC purchased a new position in shares of United Therapeutics in the fourth quarter worth $67,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $47.04 on Tuesday, hitting $281.36. 2,800,141 shares of the company's stock were exchanged, compared to its average volume of 449,050. The firm's 50-day moving average is $301.38 and its 200 day moving average is $332.82. The company has a market capitalization of $12.69 billion, a PE ratio of 12.36, a P/E/G ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 1-year low of $266.98 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the company posted $6.17 earnings per share. On average, analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on UTHR. Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Cantor Fitzgerald started coverage on shares of United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 target price on the stock. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. Finally, Morgan Stanley boosted their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research note on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $393.00.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the transaction, the executive vice president now directly owns 36,781 shares of the company's stock, valued at approximately $10,437,712.18. This trade represents a 23.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the sale, the chief financial officer now directly owns 8,118 shares of the company's stock, valued at $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,500 shares of company stock valued at $20,828,390 in the last ninety days. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.